Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 110.11$. Average daily volumn in 3 months 1.27M. Market cap 283.17B

Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 125.79$. Total volume : 1.22M. Market state POST
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price

Previous Close127.08
Day Range124.87-126.58
Bid124.72 x 900
Ask127.43 x 900
Average Volume1.27M
Market Cap283.17B
52 Week Range91.51-127.79
Trailing P/E38.35
Foward P/E30.61
Dividend (Yield %)1.26%
Ex-Dividend Date2022-08-12

Financial Details

According to Novo Nordisk A/S's financial reports the company's revenue in 2021 were 140.8B an increase( +11.11%) over the years 2020 revenue that were of 126.95B. In 2021 the company's total earnings were 47.76B while total earnings in 2020 were 42.14B( +11.9%).

Loading ...


Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Market Cap:
Total Assets:
Total Cash:

News about "Novo Nordisk A/S"


Novo Nordisk A/S – Share repurchase programme

Source from : YAHOO!Finance - 1 days ago

On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»

What Can Novo Nordisk A/S (NYSE: NVO) Expect In 2022?

Source from : stocksregister - 3 days ago

Novo Nordisk A/S (NYSE:NVO) price on Friday, December 02, rose 0.61% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $126.90. A look at the stock’s price ...See details»

Should You Invest in Novo Nordisk A/S (NVO) Stock?

Source from : Yahoo - 12 days ago

In addition, please check the fund’s top five holdings to know its best picks in 2022. ClearBridge Investments highlighted stocks like Novo Nordisk A/S (NYSE:NVO) in its Q3 2022 investor letter.See details»

Novo Nordisk A/S

Source from : CNBC - 8 days ago

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...See details»


Novo Nordisk (NVO) Q3 2022 Earnings Call Transcript

Source from : The Motley Fool on MSN - 1 month ago

Q3 2022 Earnings CallNov 02, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by. Welcome to Q3 ...See details»

Novo Nordisk A/S 2022 Q3 - Results - Earnings Call Presentation

Source from : Seeking Alpha - 1 month ago

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...See details»

Novo Nordisk A/S Class B

Source from : Morningstar%2c Inc. - 12 days ago

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...See details»

Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

Source from : Nasdaq - 1 month ago

Novo Nordisk A/S NVO reported third-quarter 2022 earnings of 86 cents per American Depositary Receipt, beating the Zacks Consensus Estimate of 84 cents. The company had reported earnings of 84 ...See details»

Novo Nordisk To Invest DKK 5.4 Bln To Expand Existing Facilities In Bagsværd, Denmark

Source from : Business Insider - 14 days ago

Novo Nordisk A/S (NVO), a Danish healthcare company, announced Tuesday its plans to invest 5.4 billion Danish kroner to expand ...See details»

Novo Nordisk: Q3 Earnings Snapshot

Source from : SFGate - 1 month ago

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported third-quarter net income of $1.95 billion. On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income ...See details»

Novo Nordisk A/S: Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

Source from : Finanznachrichten - 14 days ago

These expansions will provide capacity for developing Novo Nordisk's future oral and injectable product portfolio. "This investment in expanding our clinical API capacity in Bagsværd is an ...See details»

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Source from : Yahoo Sport Australia - 1 month ago

Bagsværd, Denmark, 4 November 2022 – This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons ...See details»


Danish drug maker Novo Nordisk to invest $744 million to expand facilities in Bagsvaerd

Source from : KFGO - 15 days ago

Danish drug maker Novo Nordisk announced on Tuesday it planned to invest 5.4 billion Danish crowns ($744.09 million) to expand its existing facilities in Bagsvaerd. The investment project is expected ...See details»

Novo Nordisk A/S – Share repurchase programme

Source from : Yahoo - 6 days ago

Bagsværd, Denmark, 30 November 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...See details»